Background: Approximately half of the patients diagnosed with localized esophageal cancer die of metastatic disease within the first 2 years following tumor resection. The development of monoclonal antibodies (MAbs) directed against epithelial cell-associated and tumor antigens has enabled the detection of single disseminated tumor cells in secondary organs. Purpose: We used MAbs directed against epithelial cell antigens (i.e., cytokeratins) to determine the proportion of patients with esophageal cancer who display isolated tumor cells in their bone marrow. In addition, we evaluated the prognostic significance of a finding of bone marrow tumor cells in patients with esophageal cancer whose tumors were completely resected. Methods: Prior to the initiation of treatment, bone marrow was aspirated from both sides of the upper iliac crests of 90 patients with squamous cell carcinoma of the esophagus. Bone marrow was also obtained from a population of 30 individuals who had not been diagnosed with cancer. Tumor cells in cytologic bone marrow preparations were detected by use of an assay that employed the MAbs CK2 (directed against cytokeratin 18), KL1 (directed against a 56 000-kd pan-cytokeratin component), and A45-B/B3 (directed against an epitope common to cytokeratins 8,18, and 19) plus the alkaline phosphatase anti-alkaline phosphatasestaining method. Bone marrow biopsies, for conventional histologic examination with Giemsa staining, were performed on 62 patients. The Kaplan-Meier method and the logrank test were used to assess disease-free and overall survival according to the
In the United States, approximately 11 300 new cases of carcinoma of the esophagus or of the esophagogastrointestinal junction were diagnosed in 1993, and 10 200 individuals died of these cancers (/) . About half of all patients with esophageal cancer have locoregional disease at diagnosis, whereas the other half have more widespread disease that is usually incurable. However, 40%-50% of the patients with apparently localized disease die of metastatic relapse within the first 2 years after tumor resection (2, 3) . It is assumed, therefore, that these patients already had occult micrometastases at the time of primary surgery
(D-
The development of monoclonal antibodies (MAbs) directed against epithelial cell-associated antigens has enabled the immunocytologic detection of single disseminated tumor cells in mesenchymal secondary organs (4) (5) (6) (7) (8) (9) (10) (11) . In most studies, bone marrow has been used as the indicator organ because it is easily accessible and is normally devoid of epithelial cells. The remarkable sensitivity and the prognostic relevance of this new diagnostic approach have been documented in several clinical studies of breast, colorectal, gastric, and lung cancers (4) (5) (6) (7) (8) (9) (10) (11) . Therefore, the standardization committee of the International Union Against Cancer (UICC) has suggested that a new subcategory, called "pMl(i)," be incorporated into the existing tumor classification scheme; pMl(i) denotes that stage of minimal systemic disease in which isolated tumor cells are present in secondary organs (12) . However, sensitive assays for the detection of micrometastatic cells in patients with esophageal cancer are currently not available.
In this study, we have applied an immunocytochemical cytokeratin detection assay that allows the identification of one epithelial tumor cell in 4 x 10 5 bone marrow cells. The purpose of the study was to determine the proportion and characteristics of patients with esophageal cancer who display isolated tumor cells in their bone marrow at the time of primary diagnosis and to evaluate whether a finding of disseminated cells is associated with an unfavorable prognosis.
Patients and Methods
Patients and Follow-up From August 1992 through February 1995, a total of 90 consecutive patients (mean age, 55.6 years) with histologically proven squamous cell carcinoma of the esophagus treated at the Department of Surgery of the Technische Universitat Miinchen (Munich, Federal Republic of Germany) were admitted to this prospective study. The study design was approved by the local institutional review board. All patients were subjected to extensive preoperative staging by use of computerized tomography, abdominal and endoscopic ultrasonography, bronchoscopy, chest radiography, and radionuclide bone scanning (2 J). The distribution of the patients by age, sex, and tumor stage is shown in Table 1 .
Three subgroups of patients were analyzed separately according to the applied treatment approach. In the first group, consisting of 31 patients, surgical resection was performed with curative intent by use of transthoracic (n = 26) or transmediastinal (n = 5) esophagectomy. The second group, containing 22 patients, received preoperative chemotherapy and radiotherapy, consisting of one cycle of fluorouracil (300 mg/m 2 , given as a continuous infusion during the period of radiation therapy) and 3000 cGy of radiation administered over a period of 3 weeks (15 fractions, 200 cGy/day, 5 days per week), followed by transthoracic en bloc esophagectomy. Preoperative chemotherapy plus radiotherapy was offered to all patients who had a good performance status (Karnofsky scale, >80%) and for whom preoperative staging had revealed locally advanced disease with a low likelihood of complete tumor removal (by primary surgical resection). Complete removal of the primary tumor (RQresection) was achieved in a total of 42 (79.2%) of the patients in groups 1 and 2. In the final group of 37 patients, only palliative, nonsurgical treatment was provided because preoperative staging and risk analysis had revealed either an unresectable tumor, distant metastasis, or a poor performance status. Thirteen of these patients had UICC stage III disease, eight had stage I disease, and 16 had stage Ha disease.
Follow-up examinations, conducted at 3-, 6-, or 12-month intervals following bone marrow aspiration, were performed in the outpatient tumor department of our hospital or by private practitioners. These examinations included an evaluation of clinical symptoms (dysphagia and weight loss) as well as radiologic examinations (computerized tomography and radionuclide bone scanning) and any possible histologic verification of unclear findings (puncture of foci suspected as metastases). Bone marrow aspirated from 30 patients with hip disease or with fractures (mean age, 47.8 years) served as control specimens to test for the specificity of the immunostaining.
Tissue Preparation
After written informed consent was received and prior to the initiation of any therapy, all patients were subjected to aspiration of 2-5 mL bone marrow from both sides of the iliac crest. These bone marrow specimens were obtained by direct puncture, using sodium citrate as an anticoagulant, and all NPatients who received palliative treatment were excluded from this analysis.
specimens from a given individual were pooled before further processing. Mononuclear cells (MNCs) were isolated by density-gradient centrifugation through Ficoll-Hypaque (Pharmacia, Freiburg, Federal Republic of Germany) at 400g for 30 minutes at room temperature and then deposited onto glass slides by cytocentrifugation at 150g for 8 minutes, also at room temperature. The number of MNCs spun onto each slide was 8x10. Additional bone biopsies were performed on 62 of the cancer patients, and paraffin-embedded sections of these specimens were examined by use of a conventional histologic method (i.e., Giemsa staining). From another subgroup of 29 patients, cryostat sections of their primary tumors were prepared and transferred onto glass slides that had been pretreated with 3-triethoxysilyl-propylamine (Merck, Darmstadt, Federal Republic of Germany).
The representative nature of the analyzed subgroups is documented by the absence of significant differences in sex, age, tumor stage, or treatment method in relationship to the entire study population.
Immunocytochemistry
The cytocentrifuge preparations were fixed with acetone for 10 minutes at room temperature, airdried, and then preincubated with antibody-free human serum (from type AB blood; diluted 1:10 with Tris-phosphate-buffered saline [Merck]) for 25 minutes to block nonspecific antibody binding. Epithelial tumor cells were identified immunocytologically using the following mouse anti-cytokeratin MAbs: 1) CK2 (immunoglobulin Gl [IgGl]; Boehringer Mannheim, Tutzing, Federal Republic of Germany), directed against cytokeratin polypeptide number 18 (13); 2) KL1 (IgGl; Dianova, Hamburg, Federal Republic of Germany), directed against a pan-cytokeratin component of 56 000 kd (14) ; and 3) A45-B/B3 (IgGl; Micromet, Munich, Federal Republic of Germany), which detects a common epitope present on a variety of cytokeratin components, including cytokeratins 8, 18, and 19 (15,16) . Each of these anti-cytokeratin MAbs was applied at optimum concentrations, ranging from 2 to 5 |ig/mL, for 45 minutes at room temperature.
For visualization of antibody binding, the sensitive alkaline phosphatase anti-alkaline phosphatase (APAAP) technique was employed, as described previously (5, 8, 10, 11) . Briefly, after incubation with a polyvalent rabbit anti-mouse immunoglobulin (1:20 dilution; Z259; Dakopatts, Hamburg, Federal Republic of Germany) for 30 minutes, the preparations were incubated for an additional 30 minutes in the presence of preformed complexes of alkaline phosphatase and mouse monoclonal anti-alkaline phosphatase antibodies (1:100 dilution; D651; Dakopatts). Both incubations were carried out at room temperature. Alkaline phosphatase activity was monitored by use of the Neufuchsin stain (17) , and endogenic formation of phosphatase activity was blocked by preincubation with levamisole. 
Statistical Analysis
The chi-squared test was used to evaluate differences between the subgroups analyzed. All reported P values are from two-sided statistical tests, and a P value of <.O5 was regarded as statistically significant. Life-table curves for the 42 patients with completely resected (RQ) tumors were estimated according to the Kaplan-Meier method, and survival (disease-free and overall) distributions were compared by use of the logrank statistic.
Results
To evaluate the reactivity of the anticytokeratin MAbs used in this study, cryostat sections from the primary tumors of a representative subgroup of 29 patients with esophageal cancer were immunostained. Homogeneous staining with MAbs KLl, A45-B/B3, and CK2 was observed in the tumor sections from 28 (96.6%), 26 (89.7%), and 17 (58.6%) patients, respectively (data not shown). Using anti-cytokeratin MAbs and the APAAP staining technique, strong immunocytologic staining, without evidence of background staining, was observed when tumor cells were present in the bone marrow specimens (Fig. 1, B) . Thus, a bone marrow preparation was scored as positive when one or more stained cells was detected. Cytokeratin-positive cells were detected in 37 (41.1%) of 90 marrow samples (Table 1 ). In 32 of these positive samples, less than 10 cells per 4 x 10 5 MNCs were found. The majority of specimens showed isolated tumor cells, whereas clusters of positive cells were observed in the samples of only five (5.6%) patients. Six (6.7%) cancer patients had specimens that stained with the MAb CK2, compared with 31 (34.4%) patients who displayed KL1-positive cells (data not shown). A representative subgroup of 43 bone marrow samples was analyzed with the MAb A45-B/B3. Ten (23.3%) of these specimens were A45-B/B3 positive, whereas 13 (30.2%) contained KLl-positive cells (data not shown). In contrast, the control specimens from disease-free patients consistently lacked any cytokeratin-positive cells, which demonstrates the specificity of the three anti-cytokeratin MAbs used in our study.
Although similar investigations have evaluated only a poorly defined number of bone marrow cells smeared on glass slides {6,18), we screened cytospin preparations, thus allowing a more precise quantitation of the stained cells. The relative proportion of cytokeratin-positive cells in our patients with esophageal cancer was between one and 82 cells per 4 x 10 5 MNCs, with no significant differences between patients diagnosed with tumors at different stages (data not shown). Assuming an average value of 10 10 nucleated cells per kilogram of body weight (19) , the calculated load of tumor cells in total bone marrow could range from 2.5 x 10 5 to 2.1 x 10 7 per kg body weight.
To compare the sensitivity of the immunocytochemical method to conventional histopathologic examination, bone marrow biopsy specimens were obtained from a representative subgroup of 62 patients. Only two (3.2%) of these specimens showed morphologically identifiable tumor cells, whereas cytokeratinpositive cells were detected in the cytocentrifuge preparations from 30 of these patients (/ > <.01; data not shown). A comparison between the results of our assay and established predictors of clinical outcome, such as UICC stage and completeness of tumor resection (R category) or the patient's sex, age, and method of treatment, revealed no obvious associations (Table 1) .
For follow-up analyses, patients who received palliative treatment only (n = 37) or who displayed residual primary tumor (Ri/2-resection; n = 11) were excluded. The remaining 42 eligible patients had completely resected (Ro) disease. Nineteen (45.2%) of these 42 patients had cytokeratin-positive cells in their bone marrow, whereas the remaining 23 (54.8%) had negative findings. Within the median follow-up period of 15.5 months (range, 6-33 months), the clinical outcome of these patients and the results of their immunocytochemical assays at primary diagnosis were significantly associated. As shown in Fig. 2 , univariate survival analyses revealed that the presence of cytokeratin-positive cells in bone marrow was predictive of reduced disease-free (P -.019) and overall {P = .036) survival. Tumor relapse was observed in 15 (79.0%) of 19 patients with positive bone marrow findings, compared with three (13.0%) of 23 patients with negative results (Table 2) . Distant metastases (liver, peritoneum, and skeleton) were detected in five (26.3%) cytokeratin-positive patients, whereas local relapse was diagnosed in 10 cases (52.6%) ( Table 2 ). In contrast, only one (4.4%) of the 23 cytokeratin-negative patients developed a distant metastasis (lung), and only two (8.7%) had local relapse (Table 2) .
Since most of the patients with tumor cells in their bone marrow displayed fewer than 10 cytokeratin-positive cells per 4 x 10 5 MNCs, it was difficult to include the concentration of cytokeratin-positive cells in our statistical analyses. Nevertheless, it should be noted that all five patients who had more than 10 cytokeratin-positive cells per 4 x 10 5 MNCs experienced relapses within the observation period. Time, mon. 
Discussion
Understanding the natural history of esophageal cancer is essential for planning successful therapeutic approaches for newly diagnosed patients. Failure to recognize early occult metastases will lead to treatment failure if therapy is aimed only at control of the local tumor burden. In this study, we identified single tumor cells disseminated to the bone marrow of 37 (41.1%) of 90 patients with squamous cell carcinoma of the esophagus by use of an immunocytochemical screening method that employed anti- Distant metastases to the liver (n = 2), peritoneum (n = 2), lung (n = 1), and skeleton (n = 1). §Two-sided P = .019 (logrank test) in comparison with cytokeratin-positive patients.
cytokeratin MAbs. We have also evaluated a small number of patients (n = 25) with adenocarcinoma of the esophagus, and we observed tumor cells in the bone marrow in 10 cases (data not shown). The described immunocytologic assay can identify tumor cell intruders, which are sometimes morphologically indistinguishable from hematopoietic bone marrow cells, at a frequency as low as 1 in 10 5 nucleated cells. This finding may explain the low sensitivity of standard histopathologic examination of bone marrow biopsies (5, 20) .
Our evaluation of control specimens from 30 disease-free patients confirms the remarkable specificity of anti-cytokeratin MAbs in the detection of epithelial cancer cells in bone marrow (5, 8, 10, 11, 21) . In contrast, the use of most MAbs directed against "epithelial cell-specific" surface proteins, such as the epithelial membrane antigen (4, 7) , requires additional morphologic verification because these antibodies frequently cross-react with hematopoietic bone marrow cells (11, 21) . In our study, the broad-spectrum MAbs KL1 and A45-B/B3 were more sensitive probes than the monospecific anti-CK18 MAb CK2, which primarily stains normal and malignant cells of simple epithelia (13) . Although immunostaining with MAb CK2 is a good marker for squamous cell carcinoma of the lung (10), its value in esophageal cancer is rather limited.
It should be noted, however, that there is no established method (i.e., "gold standard") for determining whether a patient has isolated, disseminated tumor cells in bone marrow. Although histopathologic examination of bone marrow is sometimes able to detect aggregates of tumor cells, it usually fails to detect isolated tumor cells (5) . Thus, there is no basis for evaluating the real sensitivity of a new method.
Because most of the cytokeratin-positive tumor cells that we observed were isolated, the term "micrometastasis" might be misleading, since this term suggests the presence of a cell cluster. However, tumor cell clusters were found in only five of the 90 patients analyzed in our study. Therefore, the term "isolated tumor cells in bone marrow" appears to be more accurate and has thus been suggested by the UICC standardization committee (12) . The fate of these isolated cells might be quite variable. Although a fraction of the cells may indeed represent precursors of overt skeletal metastases, others may leave the bone marrow and settle in different secondary organs, where they may encounter better "soil." This hypothesis might explain the relatively small proportion of overt skeletal metastases observed in the patients with cytokeratin-positive bone marrow cells in our study. This rare occurrence of tumor relapses in bone or bone marrow is consistent with reports in the literature (22) (23) (24) . Thus, a cytokeratin-positive bone marrow finding might indicate an increased disseminatory potential for an individual esophageal tumor, but it may not necessarily predict the site of metastatic growth. This view is consistent with the interpretation of the results of Lindemann et al. (8) in patients with colorectal cancer.
In view of the cumbersome nature of microscopic screening of stained cytologic preparations, molecular techniques permitting the processing of larger sample volumes are presently being validated in clinical studies. The detection of cytokeratin messenger RNA (mRNA) by use of coupled reverse transcription and the polymerase chain reaction (RT-PCR) has allowed identification of single cytokeratin-positive cells in bone marrow and lymph nodes (25, 26) . Although such assays are extremely sensitive, their specificity is limited by the low-level ectopic expression of cytokeratin mRNA in nonepithelial cells (25, 27) . Another limitation preventing the widespread use of RT-PCR in the detection of cytokeratinpositive squamous cell carcinoma cells in bone marrow is the possible contamination of aspirates with cytokeratin-positive skin cells. While such contamination can be discriminated by the cytologic approach used here, it cannot be distinguished by RT-PCR.
The lack of association between primary tumor stage and the incidence of isolated tumor cells in bone marrow can be explained by assuming that cells have the capacity to leave the primary tumor early in its development. This assumption is supported by the fact that four of eight patients with stage I disease already displayed tumor cells in their bone marrow. Similar behavior of tumor cells has been found for other epithelial tumors, such as non-small-cell lung cancers (28) .
The prognostic significance of detecting isolated tumor cells in bone marrow has been documented in breast, colorectal, gastric, and lung cancers (4, 6, 8, 10, 11, 18, 28) .
However, more patients need to be followed for a longer period of time to confirm the evidence to date that isolated esophageal cancer cells in bone marrow are predictive of a worse outcome, i.e., the presence of tumor cells at a secondary site indicates that the disease has become systemic. If the association is maintained, effective systemic therapy should be investigated to eliminate the disseminated tumor cells. However, current options for systemic therapy in patients with esophageal cancer are rather limited (1). Our previous analyses of micrometastatic tumor cells in the bone marrow of patients with gastrointestinal carcinomas indicated that most of these cells are in a dormant, nonproliferating state (29) , which might explain the relative ineffectiveness of chemotherapy. Nevertheless, in a first subset of 15 patients, we observed a decrease in the incidence of positive bone marrow findings after systemic chemotherapy. While six patients displayed tumor cells in bone marrow prior to therapy, one patient had such cells after therapy (data not shown). However, the total number of patients analyzed is too small to draw any firm conclusions. In addition to chemotherapy, new treatment methods, such as antibody therapy, which has been shown to be effective in preventing metastatic relapse in colon cancer (30) , may need to be evaluated in the treatment of esophageal cancer. In such treatment, the bone marrow assay described here may be used to monitor the therapeutic efficacy against micrometastatic disease.
